Peer-Reviewed Publication
NPJ Precis Oncol2025;10(1):8.December 11, 2025Journal Article
Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer.
Paolo Manca1,2, Chin-Tung Chen3, Farheen Shah4, Christina Lee3, Dylan Domenico4, Dana Omer3, Santiago Gonzalez5, Ino De Bruijn4, Samuel Ahuno4, Walid K Chatila4, Madison Darmofal4, Iman Tavassoly5, Adam J Widman1, Michael F Berger6, Brian Loomis6, Elli Papaemmanuil4, Rona Yaeger1, Asaf Zviran5, Julio Garcia-Aguilar7, Francisco Sanchez-Vega8
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5C2i Genomics Inc, New York, NY, USA.
6Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. garciaaj@mskcc.org.
8Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. sanchezf@mskcc.org.
Abstract
Optimal selection of patients with locally advanced rectal cancer for watch and wait (WW) and optimal management during follow-up remain challenging. We employed a primary-tumor-informed whole genome sequencing (WGS) assay to detect circulating tumor DNA (ctDNA) and estimate tumor fraction (TF) before, during and after neoadjuvant therapy. ctDNA was detected in 95% of baseline samples, and TF was…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans